↓ Skip to main content

A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation

Overview of attention for article published in Current Pharmaceutical Design, September 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 2,997)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Citations

dimensions_citation
109 Dimensions

Readers on

mendeley
239 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
Published in
Current Pharmaceutical Design, September 2012
DOI 10.2174/138161212802884681
Pubmed ID
Authors

Antonio Waldo Zuardi, Jose Alexandre S. Crippa, Jaime E.C. Hallak, Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Philip K. McGuire, Francisco Silveira Guimaraes

Abstract

Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile. Moreover, fMRI results strongly suggest that the antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ(9)-THC involve the striatum and temporal cortex that have been traditionally associated with psychosis. Although the mechanisms of the antipsychotic properties are still not fully understood, we propose a hypothesis that could have a heuristic value to inspire new studies. These results support the idea that CBD may be a future therapeutic option in psychosis, in general and in schizophrenia, in particular.

Twitter Demographics

The data shown below were collected from the profiles of 113 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 239 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
Israel 1 <1%
Brazil 1 <1%
Canada 1 <1%
Germany 1 <1%
Unknown 232 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 53 22%
Student > Master 46 19%
Student > Ph. D. Student 29 12%
Researcher 26 11%
Other 24 10%
Other 34 14%
Unknown 27 11%
Readers by discipline Count As %
Medicine and Dentistry 50 21%
Agricultural and Biological Sciences 34 14%
Neuroscience 31 13%
Psychology 26 11%
Pharmacology, Toxicology and Pharmaceutical Science 21 9%
Other 42 18%
Unknown 35 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 188. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2020.
All research outputs
#101,527
of 16,081,025 outputs
Outputs from Current Pharmaceutical Design
#3
of 2,997 outputs
Outputs of similar age
#830
of 156,774 outputs
Outputs of similar age from Current Pharmaceutical Design
#1
of 50 outputs
Altmetric has tracked 16,081,025 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,997 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.